Author:
Vetter Marion L.,Johnsson Kristina,Hardy Elise,Wang Hui,Iqbal Nayyar
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference66 articles.
1. American Diabetes Association. Standards of medical care in diabetes-2018: (8) Pharmacologic approaches to glycemic treatment. Diabetes Care. 2018;41(Suppl 1):S73–85.
2. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.
3. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.
4. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123–9.
5. US Food and Drug Administration (FDA). Information for healthcare professionals: exenatide (marketed as Byetta)-10/2007. 2007.
https://wayback.archive-it.org/7993/20170722190645/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124712.htm
. Accessed 19 Apr 2018.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献